Berkeley Heights-based Edge Therapeutics, a clinical-stage biotechnology company, announced Tuesday it has appointed and promoted key executives to its senior management team.
Herbert J. Faleck, D.O. has joined the company as chief medical officer, the company announced in a recent press release. He has more than 25 years of experience in clinical research. Prior to Edge, he was the chief medical officer of Celgene Cellular Therapeutics.
Andrew J. Einhorn has joined the company as chief financial officer. He has more than 10 years of experience in the pharmaceutical industry in developing and executing corporate strategies. Prior to this role, he served as co-founder and chief financial officer for Oceana Therapeutics Inc., Esprit Pharma and ESP Pharma.
Alpaslan Yaman, Ph.D. is the new vice president of operations and manufacturing. He has more than 28 years of biotech, pharma and medical device industry experience. Prior to Edge, he worked for Johnson & Johnson.
Gene Mack has joined the company as its senior director of investor relations. He has more than 14 years of experience as a senior analyst covering the biotech, life science and specialty pharmaceutical sectors for banking firms. Before this role, he was a senior biotechnology analyst at Brean Capital.
William Shatynski is the new senior director of financial reporting and controller. He has over 25 years of financial and accounting experience in both the public and private sectors. Before this role, he was senior director and controller at Insmed Inc.
Additionally, Albert Marchio has been appointed to chief accounting and operations officer.
The company has also opened its new corporate headquarters in Berkeley Heights. The property is located at 200 Connell Drive.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy